Mesterolone (Proviron dosage) is the brand name for the oral androgen Mesterolone
(1-methyldihydrotestosterone) from Schering-Plough (now Bayer). Similar
to dihydrotestosterone, Mesterolone is a strong androgen with only a
weak level of anabolic activity. Because it is similar to
dihydrotestosterone, Mesterolone is rapidly reduced to inactive diol
metabolites in muscle tissue with a higher concentration of
3-hydroxysteroid dehydrogenase. In fact, due to its extremely high
affinity for plasma binding proteins such as SHBG, Mesterolone can
actually enhance its steroid activity by replacing it with a free
unbound state. Among athletes, Mesterolone is mainly used to increase
androgen levels during thrift or preparation for competition, and as an
antiestrogens due to its ability to antagonize aromatase.
Product History: According to company records, Schering-Plough developed Mesterolone in 1934. As an anabolic steroid, Mesterolone is
ancient. It is the first clinical practice drug to treat
"hormone-related diseases." Therefore, Mesterolone was developed at
about the same time as methyltestosterone (1935) and testosterone
propionate (1937), both of which are very old agents. Mesterolone has
the efficacy and safety of clinical records in the flood season and is
still widely used in clinical care today. Commonly used in men for the
treatment of decreased physical and mental abilities caused by age and
low androgen levels, low libido caused by insufficient androgen levels,
hypogonadism (men before and after the spring period) and infertility
(Mesterolone can improve the quality and quantity of sperm in specific
situations). Mesterolone may be controversial as a fertility adjuvant,
and anabolic/androgenic steroids are generally associated with
infertility. This is also one of the misunderstandings of athletes on
testosterone. Because of its androgenic nature, it is able to minimize
the inhibition of gonadotropins in normal therapeutic doses, rather than
because it increases the production of pro-chimogenin. Because it does
not inhibit gonadotropins, the drug can supplement the androgens
necessary for sperm production. It is well known that androgens have a
direct stimulating effect on sperm production and also affect sperm
transport and maturation by reacting epididymis, tubular structures and
seminal vesicles. Therefore, these hormones are not all inhibitory.
Mesterolone appears to have a unique positive impact on certain male
fertility because its potential stimulating effect on sperm count and
quality is not offset by gonadotropin inhibition. Mesterolone is widely
produced and sold by Bayer (formerly Lingya) and has a presence in more
than 30 countries around the world. Although Bayer has other agents in
other markets, such as mestoranum and provironum, the most common trade
name is proviron. In addition, other vendors have sold Mesterolone in
the past few years, with brand names including: Pluriviron (Asche,
Germany), Vistimon (jenepharm, Germany), and Restore (Brown & Burke,
India). Even though Mesterolone's history of use is safe and effective,
the FDA has never approved its entry into the US market. Today,
Mesterolone can still be seen in the country. Bayer is still its main
global supplier, but in rare cases it should still be able to see other
brand names.
Structural features: Mesterolone (Proviron) is a modified form of dihydrotestosterone. The difference is that a methyl group is added at
the carbon 1, which helps protect the hormone from liver damage during
oral administration. The same structural modifications are also used for
oral metoprolol tablets. The alkylation reaction at a specific position
slows the metabolism of the steroid during the first passage through
the liver, although it is far less pronounced than the c-17 alpha
alkylated steroid. The overall bioavailability of Mesterolone remains
much lower than that of c-17 alpha alkylated oral steroids, but
Mesterolone is sufficiently resistant to achieve therapeutically
beneficial blood levels. Mesterolone also has a strong binding affinity
for sex hormone binding globulin and can be used to replace other
steroids that bind weaker to SHBG. Side effects (estrogen): Mesterolone
is not aromatized by the body and no estrogen is detected. Therefore,
when using Mesterolone, the sterile line uses antiestrogens. Because
Mesterolone does not cause gynecomastia, water retention or other
estrogen-related side effects in men. It is believed that Mesterolone
can be used as an anti-aromatase in the body to prevent or slow the
conversion of steroids to estrogen. The effect is a bit similar to
Ruining, but not so deep. The antiestrogenic properties of Mesterolone
are not unique and many other steroids show similar activity. For
example, dihydrotestosterone and tacroles are successfully used to treat
male breast development and breast cancer due to strong androgenic and
potential anti-estrogen. It has been suggested that noxan can be used to
reduce aromatase activity, since noxe is more resistant to estrogen
conversion (the most active part of the aromatics is the liver). The
anti-estrogenity of all of these compounds may be due to their
competition with other substrates for binding to aromatase. Because
aromatase binds to steroids but does not alter it, it is temporarily
blocked from interacting with other hormones.
